Fund shareholders of Neurogene Inc
ISIN US64135M1053 · United States · LEI 529900A7VIY892SZVW73
- Fund shareholders
- 114
- Of which ETFs
- 22 92 other funds
- Value held
- 46.9M $
- Share of capital
- 10.7 % of 20M shares on Aug 7, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Total Stock Market Index Trust John Hancock Variable Insurance Trust | 243 | 4.9K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| VIP Total Market Index Portfolio Variable Insurance Products Fund II | 224 | 4.5K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ULTRA SMALL CAP PROFUND ProFunds | 128 | 3.3K $ | 0.01 % | 0.00 % | as of Apr 30, 2026 ↗ |
| State Street Balanced Index Fund STATE STREET INSTITUTIONAL INVESTMENT TRUST | 69 | 1.4K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Russell 2000 2x Strategy Fund Rydex Dynamic Funds | 50 | 1K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| PROFUND VP ULTRA SMALL CAP ProFunds | 38 | 766.1 $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| PROFUND VP SMALL CAP ProFunds | 29 | 584.6 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Russell 2000 Fund Rydex Series Funds | 23 | 463.7 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 21 | 547.9 $ | 0.01 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 14 | 282.2 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Columbia Research Enhanced Small Cap ETF Columbia ETF Trust I | 12 | 241.9 $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 10 | 234.9 $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 3 | 70.5 $ | 0.01 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 3 | 60.5 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 0.92 % | as of Apr 30, 2026 ↗ |
| Meridian Small Cap Growth Fund Meridian Fund Inc | 0.65 % | as of Mar 31, 2026 ↗ |
| iShares Neuroscience and Healthcare ETF iShares Trust | 0.34 % | as of Apr 30, 2026 ↗ |
| Fidelity Advisor Biotechnology Fund Fidelity Advisor Series VII | 0.33 % | as of Apr 30, 2026 ↗ |
| Ultra-Small Company Market Fund Bridgeway Funds, Inc. | 0.31 % | as of Mar 31, 2026 ↗ |
| ALPS Medical Breakthroughs ETF ALPS ETF TRUST | 0.24 % | as of Feb 28, 2026 ↗ |
| Franklin Genomic Advancements ETF Franklin Templeton ETF Trust | 0.17 % | as of Mar 31, 2026 ↗ |
| State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF SPDR SERIES TRUST | 0.09 % | as of Mar 31, 2026 ↗ |
| Nationwide Bailard Small Cap Value Fund Nationwide Mutual Funds | 0.08 % | as of Apr 30, 2026 ↗ |
| Small Company Value Portfolio Wilshire Mutual Funds Inc | 0.07 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 114 | +9 | 2,148,997 | +11.4 % |
| 2026Q1 | 105 | +10 | 1,929,423 | +24.1 % |
| 2025Q4 | 95 | -1 | 1,555,120 | -23.5 % |
| 2025Q3 | 96 | -17 | 2,031,985 | -18.9 % |
| 2025Q2 | 113 | -2 | 2,504,806 | -12.8 % |
| 2025Q1 | 115 | +3 | 2,871,991 | -10.4 % |
| 2024Q4 | 112 | +65 | 3,203,695 | +77.2 % |
| 2024Q3 | 47 | +30 | 1,807,796 | +68.1 % |
| 2024Q2 | 17 | +7 | 1,075,689 | +451.5 % |
| 2024Q1 | 10 | 195,043 |
Institutional managers
92 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | 1,717,127 | 34.6M $ | as of Mar 31, 2026 |
| Redmile Group, LLC | 1,459,599 | 29.4M $ | as of Mar 31, 2026 |
| Casdin Capital, LLC | 1,420,361 | 28.6M $ | as of Mar 31, 2026 |
| RTW INVESTMENTS, LP | 1,362,456 | 27.5M $ | as of Mar 31, 2026 |
| EcoR1 Capital, LLC | 1,271,342 | 25.6M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 1,005,070 | 20.3M $ | as of Mar 31, 2026 |
| BAKER BROS. ADVISORS LP | 991,691 | 20M $ | as of Mar 31, 2026 |
| Trails Edge Capital Partners, LP | 782,787 | 15.8M $ | as of Mar 31, 2026 |
| Balyasny Asset Management L.P. | 718,389 | 14.5M $ | as of Mar 31, 2026 |
| TORONTO DOMINION BANK | 681,337 | 13.7M $ | as of Mar 31, 2026 |
| JENNISON ASSOCIATES LLC | 527,685 | 10.6M $ | as of Mar 31, 2026 |
| ArrowMark Colorado Holdings LLC | 524,796 | 10.6M $ | as of Mar 31, 2026 |
| GREAT POINT PARTNERS LLC | 500,000 | 10.1M $ | as of Mar 31, 2026 |
| CITADEL ADVISORS LLC | 387,031 | 7.8M $ | as of Mar 31, 2026 |
| FMR LLC | 382,647 | 7.7M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 313,005 | 6.3M $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 285,239 | 5.8M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 279,003 | 5.6M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 204,809 | 4.1M $ | as of Mar 31, 2026 |
| UBS Group AG | 185,679 | 3.7M $ | as of Mar 31, 2026 |
| BLAIR WILLIAM & CO/IL | 168,218 | 3.4M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 107,714 | 2.2M $ | as of Mar 31, 2026 |
| DEUTSCHE BANK AG\ | 106,255 | 2.1M $ | as of Mar 31, 2026 |
| Rock Springs Capital Management LP | 104,339 | 2.1M $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 97,621 | 2M $ | as of Mar 31, 2026 |
Cite this page
Titelia. "Fund shareholders of Neurogene Inc". https://titelia.com/en/stocks/neurogene-inc-US64135M1053